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Abstract
Objective: The aim of this study was to determine the effect of vitamin D and probiotic co-administration on mental
health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome (PCOS).
Methods: This randomized, double-blinded, placebo-controlled clinical trial was carried out on 60 subjects, aged 18–
40 years old. Subjects were randomly allocated to take either 50,000 IU vitamin D every 2 weeks plus 8 × 109 CFU/day
probiotic (n = 30) or placebo (n = 30) for 12 weeks.
Results: Vitamin D and probiotic co-supplementation, compared with the placebo, significantly improved beck
depression inventory [β (difference in the mean of outcomes measures between treatment groups) − 0.58; 95% CI,
− 1.15, − 0.02; P = 0.04], general health questionnaire scores (β − 0.93; 95% CI, − 1.78, − 0.08; P = 0.03) and depression,
anxiety and stress scale scores (β − 0.90; 95% CI, − 1.67, − 0.13; P = 0.02). Vitamin D and probiotic co-supplementation
was associated with a significant reduction in total testosterone (β − 0.19 ng/mL; 95% CI, − 0.28, − 0.10; P < 0.001),
hirsutism (β − 0.95; 95% CI, − 1.39, − 0.51; P < 0.001), high-sensitivity C-reactive protein (hs-CRP) (β − 0.67mg/L; 95% CI,
− 0.97, − 0.38; P < 0.001) and malondialdehyde (MDA) levels (β − 0.25 μmol/L; 95% CI, − 0.40, − 0.10; P = 0.001), and a
significant increase in total antioxidant capacity (TAC) (β 82.81mmol/L; 95% CI, 42.86, 122.75; P < 0.001) and total
glutathione (GSH) levels (β 40.42 μmol/L; 95% CI, 4.69, 76.19; P = 0.02), compared with the placebo.
Conclusions: Overall, the co-administration of vitamin D and probiotic for 12 weeks to women with PCOS had beneficial
effects on mental health parameters, serum total testosterone, hirsutism, hs-CRP, plasma TAC, GSH and MDA levels.
Trial Registration: This study was retrospectively registered in the Iranian website (www.irct.ir) for registration of clinical
trials (IRCT20170513033941N37).
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Introduction
Polycystic ovarian syndrome (PCOS) is one of the most
frequent gynecological endocrinopathy that occurs in
premenopausal females [1]. Although the physiopathology
of this syndrome is complicated and not yet completely
elucidated; hyperandrogenism, inflammation and its
permanent companions, and oxidative damage play cen-
tral roles in PCOS [2, 3]. In fact, elevated androgen values
may be due to the inflammatory response of the ovarian
cells by free-radical species [4]. Furthermore, increased
systemic inflammatory markers such as C-reactive protein
(CRP) are related to the increased risk of type 2 diabetes
mellitus (T2DM) and cardiovascular disease [5]. A recent
meta-analysis documented that mental health disorders
are common in patients with PCOS [6]. Also, hirsutism,
menstrual irregularity, and acne impair the quality of life
(QOL) in these women [7].
There is growing evidence suggesting the synergistic im-
pact of combined vitamin D and probiotic administration
on metabolic disorders, especially in patients with vitamin
D deficiency, which might alleviate mental health parame-
ters, and biomarkers of inflammation and oxidative stress
in patients with metabolic syndrome and related disorders.
The basis of this approach relies on probiotics effect in-
creasing vitamin D levels [8]. In addition, probiotics might
have synergistic effects with vitamin D, through improving
the expression of vitamin D receptors [9]. Therefore,
modulating the microbiota-gut-brain axis by probiotics
plus improving vitamin D levels might provide a novel
target to treat mental and metabolic disorders. Prior studies
have documented that vitamin D deficiency (VDD) is
prevalent among women with PCOS [10, 11]. Vitamin D
deficiency is associated with elevated insulin resistance, and
increased levels of total testosterone and dehydroepian-
drosterone sulfate (DHEAS) in patients with PCOS [12].
Recent evidence showed that vitamin D at physiologic
levels has a beneficial role on endometrial receptivity,
whereas an excess of this molecule plays a detrimental role
on oocytes development and embryo quality, probably due
to its anti-estrogenic effect [13]. In addition, vitamin D was
demonstrated to exert many physiological activities during
the very early stages of gestation in perfect synchrony with
progesterone [14]. In a meta-analysis, Akbari et al. [15]
indicated that vitamin D administration to women with
PCOS had beneficial impact on systemic inflammatory
markers and oxidative damage. However, in another
meta-analysis, vitamin D intake did not influence hormonal
status in patients with PCOS [16]. Furthermore, taking
50,000 IU vitamin D for 12 weeks by patients with PCOS
and VDD did not affect clinical status and hormonal pro-
files [17]. On the other hand, extensive evidence reveal that
dysbiosis of gut microflora is involved in the pathogenesis
of metabolic disturbances in PCOS [18]. Probiotics, as non-
pathogenic micro-organisms, have shown promising effects
on metabolic abnormalities such as increased inflammatory
factors, oxidative stress, insulin resistance, and atherogenic
dyslipidemia [19]. A 12-week trial using probiotic supple-
ments in women with PCOS led to the amelioration of
androgenic profiles, oxidative stress parameters and CRP
concentrations [20].
Given the anti-inflammatory and antioxidant impacts of
probiotic and vitamin D, we hypothesized that co-admin
istration of both supplements might have synergistic effects
on clinical status and biochemical parameters of women
with PCOS. Therefore, we performed this trial to determine
the impact of probiotic and vitamin D co-supplementation
on hirsutism, mental health status, hormonal profiles, and
biomarkers of inflammation and oxidative damage in
patients with PCOS.
Subjects and methods
Participants
This randomized double-blinded, placebo-controlled trial
was registered in the Iranian website for registration of clin-
ical trials (http://www.irct.ir: IRCT20170513033941N37)
and followed the Declaration of Helsinki and Good Clinical
Practice guidelines. This investigation was carried out
among 60 women with PCOS, diagnosed based on the
Rotterdam criteria [21], with the body mass index (BMI) in
the range of 17–34 kg/m2 and insulin resistance in the
range of 1.4–4, aged 18–40 years old whom referred to the
Naghavi Clinic in Kashan, Iran, between July and October
2018. The study was approved by the ethics committee of
National Institute for Medical Research Development of
Iran (NIMAD). Written informed consent was taken from
all participants prior to the initiation of the trial. Exclusion
criteria were as follows: pregnancy, lactation, adrenal hyper-
plasia, androgen-secreting tumors, hyperprolactinemia, thy-
roid dysfunction, and diabetes, women with psychological
or psychiatric comorbidities such as anxiety or depressive
symptoms at the enrollment.
Supplementation
Subjects were randomized to take either 50,000 IU vitamin
D every 2 weeks plus 8 × 109 CFU/day probiotic (n = 30) or
placebo (n = 30) for 12 weeks. Probiotic capsule contained
four viable and freeze-dried strains: Lactobacillus acidoph-
ilus, Bifidobacterium bifidum, Lactobacillus reuteri and
Lactobacillus fermentum (2 × 109 CFU/g each). These are
the basic minimal criteria which are considered in a
high-quality probiotic supplement. Little is known about
the ideal type and the dosage of probiotic used for patients
with PCOS, so we selected the supplement and its dose
based on previous published studies in diabetic patients
with coronary heart disease [19]. Vitamin D, probiotic and
placebos (corn oil and starch, respectively) were produced
by Zahravi Pharmaceutical Company (Tabriz, Iran),
LactoCare®, Zisttakhmir Company (Tehran, Iran) and Barij
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Essence Pharmaceutical Company (Kashan, Iran), respect-
ively. They were completely identical in terms of their
appearance, color, shape, size, smell, taste and packaging.
Random assignment was conducted using computer-gener-
ated numbers. Randomization and allocation concealment
were carried out for both the researchers and participants,
by a trained staff at the gynecology clinic. The compliance
rate was assessed by quantifying serum 25(OH) vitamin D
levels. Intake of the probiotic, vitamin D3, and placebo cap-
sules was monitored through asking participants to return
the medication containers. To increase compliance rate, all
patients received brief daily cell phone reminders to take
the supplements. All subjects completed a 3-day diet recall
at weeks 0, 4, 9 and 12 of the intervention. Daily macro-
and micro-nutrient intakes were calculated using nutrition-
ist IV software (First Databank, San Bruno, CA).
Assessment of outcomes
Hormonal profiles were considered as the primary out-
come. Mental health parameters, and biomarkers of
inflammation and oxidative stress were recognized as
the secondary outcomes.
Clinical measures
Hirsutism was evaluated using a modified Ferriman-Gallwey
(mFG) scoring system as 9 body areas including the upper
lip, chin, chest, upper abdomen, lower abdomen, thighs,
back, arm, and buttocks were investigating for hair;
from 0 (no hair) to 4 (frankly virile) [22, 23]. Mental health
was judged with beck depression inventory (BDI) [24], gen-
eral health questionnaire-28 (GHQ-28) [25] and depression
anxiety and stress scale (DASS) [26] at baseline and after
the 12-week intervention. Quality of sleep was determined
using PSQI [27].
Biochemical assessment
Fasting blood samples (10ml) were collected at baseline
and the end of the intervention at Kashan reference labora-
tory. Serum total testosterone and sex hormone-binding
globulin (SHBG) with inter- and intra-assay with inter- and
intra-assay CVs below 7% were quantified using ELISA kits
(DiaMetra, Milano, Italy). Serum 25-hydroxyvitamin D
concentrations were determined using an ELISA kit (IDS,
Boldon, UK) and enzyme-linked immunosorbent assay with
inter- and intra-assay CVs below 7%. Serum high sensitivity
C-reactive protein (hs-CRP) concentrations were measured
using an ELISA kit (LDN, Nordhorn, Germany) with inter-
and intra-assay CVs below 7%. The plasma NO levels were
measured using Griess method [28], total antioxidant cap-
acity (TAC) concentrations using Benzie and Strain method
[29], total glutathione (GSH) using Beutler method [30]
and malondialdehyde (MDA) concentrations thiobarbituric
acid reactive substances spectrophotometric test [31] with
CVs below 5%.
Sample size
We used a randomized clinical trial sample size calcula-
tion formula where type one (α) and type two errors (beta)
were 0.05, and 0.20 (power = 80%), respectively. According
to a previous published study [32], we used 0.48 ng/mL as
the difference in mean (d) and 0.60 ng/mL as SD for total
testosterone as the key variable. Using the formula, we
needed 25 participants in each group; after allowing for 5
dropouts in each group, the final sample size was 30 per-
sons in each group. The standardized effect size was equal
to 0.48/0.60 = 0.8 which is considered as a large effect size
according to Cohen [33]. Using SD = 0.60, we had at least
80% power (probability) of detecting a difference equal to
or greater than 0.48 (if it really exists) as statistically
significant at the 5% level.
Statistical analyses
The Kolmogorov-Smirnov test was conducted to deter-
mine the normality of data. Differences in anthropometric
measurements and dietary intakes between treatment
groups were determined using independent-sample t-tests.
Multiple linear regression models were used to assess the
treatment effects on study outcomes, after adjusting for
confounding parameters, including age and BMI. The
effect sizes (β) were presented as the mean differences
with 95% confidence intervals between two groups.
P-values < 0.05 were considered statistically significant. All
statistical analyses were done using the Statistical Package
for Social Science version 18 (SPSS Inc., Chicago, Illinois,
USA).
Results
As demonstrated in the study flow diagram (Fig. 1), 60
participants [placebo (n = 30) and vitamin D plus probiotic
supplements (n = 30)] completed the trial. No side effects
were reported following co-administration of vitamin D
and probiotic capsules in patients with PCOS throughout
the study.
Mean age, height, baseline and end-of-trial weight and
BMI of study participants were not statistically different
between both groups (Table 1). There was no statistically
significant difference in terms of dietary macro- and
micro-nutrient intakes between vitamin D plus pro-
biotic, and placebo groups (Data not shown).
After the 12-week intervention, vitamin D and probiotic
co-supplementation significantly improved BDI [β (differ-
ence in the mean of outcomes measures between treatment
groups) -0.58; 95% CI, − 1.15, − 0.02; P = 0.04], GHQ
(β − 0.93; 95% CI, − 1.78, − 0.08; P = 0.03) and DASS
(β − 0.90; 95% CI, − 1.67, − 0.13; P = 0.02), compared with
the placebo (Table 2). Vitamin D and probiotic
co-supplementation was associated with a significant reduc-
tion in total testosterone (β − 0.19 ng/mL; 95% CI, − 0.28,
− 0.10; P < 0.001), hirsutism (β − 0.95; 95% CI, − 1.39,
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− 0.51; P < 0.001), hs-CRP (β − 0.67mg/L; 95% CI, − 0.97,
− 0.38; P < 0.001) and MDA levels (β − 0.25 μmol/L; 95%
CI, − 0.40, − 0.10; P = 0.001), and a significant increase
in TAC (β 82.81 mmol/L; 95% CI, 42.86, 122.75; P <
0.001) and GSH levels (β 40.42 μmol/L; 95% CI, 4.69,
76.19; P = 0.02) compared with the placebo.
Co-supplementation did not affect serum SHBG and
plasma NO levels, as well as acne and alopecia.
Discussion
In the current study, we investigated the effects of vita-
min D and probiotic co-supplementation for 12 weeks
on mental health, hormonal, inflammatory and oxidative
stress parameters among women with PCOS. We found
that the co-administration of vitamin D and probiotic
for 12 weeks to women with PCOS had beneficial effects
on mental health parameters, serum total testosterone,
hirsutism, hs-CRP, plasma TAC, GSH and MDA levels,
but did not affect serum SHBG, plasma NO levels, acne
and alopecia.
Effects on mental health
We found vitamin D and probiotic co-administration for
12 weeks to women with PCOS significantly reduced BDI,
GHQ and DASS scores, yet did not influence PSQI index.
Prior reports have documented the association between
mood disorders and gastrointestinal microbiota, indicating
the role of the gut-brain axis in the physiopathology of
clinical depression [34]. Moreover, microflora biosynthesis
and the regulation of neurotransmitters, including GABA
[35] and serotonin [36] are probable mechanisms that gut
bacteria can affect mental status. In a recent meta-analysis,
Fig. 1 Summary of patient flow diagram
Table 1 General characteristics of study participants1
Placebo group (n = 30) Vitamin D plus probiotic group (n = 30) P2
Age (y) 25.4 ± 5.1 24.4 ± 4.7 0.40
Height (cm) 162.9 ± 6.8 163.0 ± 8.5 0.97
Weight at study baseline (kg) 66.3 ± 11.4 64.8 ± 13.2 0.63
Weight at end-of-trial (kg) 65.8 ± 11.1 64.1 ± 13.0 0.57
Weight change (kg) -0.5 ± 1.2 −0.7 ± 0.5 0.31
BMI at study baseline (kg/m2) 25.1 ± 4.9 24.3 ± 4.2 0.51
BMI at end-of-trial (kg/m2) 24.9 ± 4.8 24.1 ± 4.1 0.46
BMI change (kg/m2) −0.2 ± 0.5 − 0.3 ± 0.2 0.35
1Data are means± SDs
2Obtained from independent t-test
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probiotic consumption did not affect depressive symptoms
in healthy people [37]. In addition, Ju et al. [38] indicated
an inverse relationship between serum vitamin D values
and depression on a pooled meta-analysis of cross-sectional
and cohort studies. Vitamin D contributes to various brain
processes such as neuroprotection, neuroimmunomodula-
tion, and brain development, suggesting that mental health
disorders may be correlated with VDD [39, 40]. Vitamin D
may ameliorate mental health disorders, via up-regulation
of tyrosine hydroxylase gene expression and augmentation
of the bioavailability of various neurotransmitters, including
norepinephrine and dopamine [41]. Furthermore, vitamin
D intake had an insignificant impact on depression in
adults [42]. On the other hand, taking oral preparations of
isoflavones (40mg), calcium (500mg) vitamin D (300 IU)
and inulin (3 g) for 12months by menopausal women sig-
nificantly improved quality of life, sexual function, body
composition and metabolic parameters [43]. Unlike, Raygan
et al. [44] demonstrated that consumption of 50,000
IU/biweekly cholecalciferol plus one probiotic capsule
daily by type 2 diabetic patients with ischemic heart
disease significantly improved depression and anxiety
indices. The synergism between the immunomodula-
tory, antioxidant, and anti-inflammatory properties of
both supplements might enhance their impact on
mental health parameters.
Effects on hirsutism and hormonal profiles
Our results provided evidence that vitamin D and pro-
biotic co-supplementation for 12 weeks in women with
PCOS significantly improved hirsutism and total testos-
terone concentrations, but did not affect SHBG values.
To date, little is known about drug metabolism in
women with PCOS. This important gap in the literature
could have significant implications for therapeutic ap-
proaches and future perspectives: first, the dosage of drugs
commonly used for the treatment of women with PCOS
should be tailored according to each patient’s characteris-
tics; second, implementing new clinical trials in order to
identify the best pharmacologic strategy for patients with
PCOS undergoing in vitro fertilization (IVF); finally, advis-
ing to create an international expert panel to investigate
the drug metabolism in women with PCOS [45]. Cumula-
tive evidence from IVF studies has proposed that
fertilization rate decreases significantly with increasing
levels of 25OH-D in follicular fluid; in addition, vitamin D
concentrations in the follicular fluid are negatively corre-
lated with the quality of embryos and the higher values of
vitamin D are associated with lower possibility to achieve
pregnancy [13]. In addition, vitamin D is involved in the
modulation of the reproductive process in women due to
the expression of VDR and 1α-hydroxylase in reproductive
tissues, including ovary, uterus, placenta, pituitary and
Table 2 Mental health parameters and metabolic profiles at baseline and after the 12-week intervention in women with polycystic
ovary syndrome that received either vitamin D plus probiotic supplements or placebo
Variables Placebo group (n = 30) Vitamin D plus probiotic group
(n = 30)
Difference in outcome measures between vitamin D
plus probiotic and placebo groups1
Baseline Week 12 Baseline Week 12 β (95% CI) P2
25-hydroxyvitamin D (ng/mL) 12.9 ± 3.2 13.3 ± 2.7 11.1 ± 4.1 24.4 ± 5.6 12.69 (11.09, 14.29) < 0.001
BDI total scores 13.8 ± 3.6 13.2 ± 3.7 12.9 ± 4.1 11.9 ± 3.4 −0.58 (−1.15, − 0.02) 0.04
GHQ scores 42.7 ± 9.1 41.9 ± 8.9 40.4 ± 6.7 38.7 ± 6.8 −0.93 (−1.78, − 0.08) 0.03
DASS scores 82.5 ± 11.8 80.8 ± 12.4 81.5 ± 12.2 78.9 ± 12.3 −0.90 (−1.67, − 0.13) 0.02
PSQI 7.5 ± 2.8 6.5 ± 3.0 7.8 ± 2.7 5.8 ± 2.1 −0.73 (−2.11,-0.63) 0.28
Total testosterone (ng/mL) 1.1 ± 0.4 1.1 ± 0.3 1.0 ± 0.3 0.9 ± 0.2 −0.19 (− 0.28, − 0.10) < 0.001
SHBG (nmol/L) 40.2 ± 5.0 40.3 ± 5.3 38.4 ± 5.9 39.6 ± 5.7 0.92 (−0.45, 2.31) 0.18
mF-G scores 13.9 ± 3.0 13.6 ± 3.0 14.98 ± 3.2 13.5 ± 3.3 −0.95 (−1.39, − 0.51) < 0.001
hs-CRP (mg/L) 3.7 ± 1.0 3.8 ± 1.3 3.8 ± 1.1 3.2 ± 0.8 −0.67 (− 0.97, − 0.38) < 0.001
NO (μmol/L) 33.3 ± 4.9 32.3 ± 5.5 34.2 ± 1.0 33.6 ± 0.8 0.37 (−0.48, 1.23) 0.38
TAC (mmol/L) 835.1 ± 101.7 830.9 ± 93.8 850.5 ± 82.7 919.2 ± 85.4 82.81 (42.86, 122.75) < 0.001
GSH (μmol/L) 475.8 ± 71.7 491.7 ± 81.0 510.4 ± 99.3 556.5 ± 97.2 40.42 (4.69, 76.15) 0.02
MDA (μmol/L) 2.7 ± 0.5 2.6 ± 0.5 2.9 ± 0.3 2.5 ± 0.2 −0.25 (−0.40, −0.10) 0.001
Data are mean ± SDs
1“Outcome measures” refers to the change in values of measures of interest between baseline and week 12. β [difference in the mean outcomes measures
between treatment groups (vitamin D plus probiotic group = 1 and placebo group = 0)]
2Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age and baseline BMI)
BDI, beck depression inventory; DASS, depression anxiety and stress scale; GHQ, general health questionnaire; GSH, total glutathione; hs-CRP, high-sensitivity C-
reactive protein; mF-G, modified Ferriman Gallwey; MDA, malondialdehyde; NO, nitric oxide; PSQI, Pittsburgh Sleep Quality Index; SHBG, sex hormone-binding
globulin; TAC, total antioxidant capacity
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hypothalamus [46]. Combined therapy with vitamin D and
probiotic may have the positive effects on outcome of
assisted reproductive technologies. Earlier, it was reported
that taking myo-inositol plus melatonin showed an im-
proved number of good quality oocytes and embryos, with
reduced follicle stimulating hormone levels and days of
treatment during cycles IVF [47]. Maktabi et al. [17]
showed that the intake of cholecalciferol (50,000 IU/
biweekly for 12 weeks) by patients with PCOS did not
influence hirsutism, total testosterone, and SHBG
levels. Furthermore, taking high-dose vitamin D3
(12,000 IU/day cholecalciferol) for 3 months by patients
with PCOS did not affect androgen profiles (total- and
free testosterone levels) [48]. In a meta-analysis, probiotic
supplementation had no significant effect on DHEAS
levels [49].
Hyperandrogenism, a hallmark of PCOS, contributed to
clinical features of this syndrome such as acne, hirsutism,
menstrual disturbances, and anovulation [50]. It has been
shown that reduction in androgen concentrations is corre-
lated with the amelioration in ovulatory functions, decreas-
ing hirsutism, and improving QOL [51, 52]. Probiotic may
improve androgenic profiles via elevating insulin sensitivity,
enhancing absorption and digestion of dietary nutrients,
modulating gut microflora and gut-brain axis [53, 54]. Im-
pact of vitamin D on activity and expression of various en-
zymes related to the steroidogenesis pathway may explain
the decrement in circulating total testosterone concentra-
tions [55]. We hypothesized that combination therapy with
vitamin D and probiotic in patients with PCOS may work
better than a single supplementation alone. Combined vita-
min D and probiotic supplementation might also have a
strong synergistic effect on hormonal profiles and bio-
markers of inflammation and oxidative stress. In a study by
Jamilian et al. [56], it was seen that vitamin D and probiotic
co-supplementation in women with gestational diabetes
had beneficial effects on metabolic status compared with
probiotic alone. Furthermore, probiotics might have syner-
gistic effects with vitamin D through improving the expres-
sion of vitamin D receptors [9]. The majority of subjects
in this study had vitamin D deficiency, so decreased
inflammation and oxidative stress by vitamin D and
probiotic may improve hormonal profiles. To our best
knowledge, data on the effects of vitamin D plus pro-
biotic supplementation, compared with only vitamin D
or probiotic, on hormonal profiles, and biomarkers of in-
flammation and oxidative stress are limited. Therefore,
further studies are required with single supplementation
of each compared with co-supplementation to assess the
beneficial effects on metabolic profiles.
Effects on biomarkers of inflammation and oxidative stress
Our results revealed that combined vitamin D and
probiotic administration to women with PCOS led to a
significant reduction in serum hs-CRP and plasma MDA
levels, and a significant elevation in plasma GSH and TAC
levels after 12 weeks. Based on current evidence, vitamin D
and probiotics may have beneficial impact on inflam-
mation and oxidative damage. Razzaghi et al. [57] indi-
cated that vitamin D supplementation for 12 weeks to
patients with diabetic foot ulcer had beneficial effects
on hs-CRP and MDA levels, but did not affect TAC
and GSH levels. In a recent meta-analysis of RCTs,
Mansournia et al. [58] showed that vitamin D intake
improved markers of oxidative damage and inflamma-
tion in diabetic people. In another meta-analysis, vita-
min D intake caused a significant reduction in hs-CRP
values [59]. On the other hand, the consumption of
probiotic supplements for 12-week by women with
PCOS decreased CRP and MDA levels [20]. In addition,
taking probiotic for 12 weeks by patients with multiple
sclerosis had favorable influences on a few systemic in-
flammatory markers and oxidative stress [60]. However,
in a meta-analysis performed among subjects with
T2DM, probiotic use did not affect CRP concentrations
[61]. Also, vitamin D consumption had no significant
impact on inflammatory biomarkers in overweight and
obese people [62]. Previous published reports demon-
strated controversial findings regarding the impact of
vitamin D and probiotic supplementation on markers
of inflammation and oxidative damage. This may be
due to the variations in study conditions, different dos-
ages of supplements, and differences in intervention
period. Increased oxidative damage and inflammatory
cytokines are related to increased risk of hyperandro-
genism, insulin resistance, cardiovascular events, and
diabetes in PCOS [63, 64]. Probiotic consumption may
reduce inflammatory cytokines, lipid peroxidation, and
oxidative damage via producing short chain fatty acid
in the intestine and reduction in generation of hydro-
gen peroxide radicals [65]. Furthermore, vitamin D can
suppress nuclear transcription factor kappa-B and de-
crease the production of free radicals and pro-
inflammatory cytokines [66].
The present trial has few limitations. We did not de-
termine the loads of fecal bacteria and microbiome
characterization before, during, and after intervention.
Moreover, we did not investigate the impact of vitamin
D and probiotic co-administration on other markers of
oxidative damage and inflammation.
Conclusions
Overall, the co-administration of vitamin D and pro-
biotic for 12 weeks to women with PCOS had beneficial
effects on mental health parameters, serum total testos-
terone, hirsutism, hs-CRP, plasma TAC, GSH and MDA
levels, but did not affect serum SHBG, plasma NO
levels, acne and alopecia.
Ostadmohammadi et al. Journal of Ovarian Research            (2019) 12:5 Page 6 of 8
Abbreviations
GSH: total glutathione; hs-CRP: high-sensitivity C-reactive protein;
MDA: malondialdehyde; mF-G: modified Ferriman Gallwey; NO: nitric oxide;
PCOS: polycystic ovary syndrome; SHBG: sex hormone-binding globulin;
TAC: total antioxidant capacity
Acknowledgements
Not applicable.
Availability of data and material
The primary data for this study is available from the authors on direct
request.
Author contributions
ZA contributed in conception, design, statistical analysis and drafting of the
manuscript. VO, MJ and FB contributed in data collection and manuscript
drafting. All authors approved the final version for submission. ZA supervised
the study.
Funding
Research reported in this publication was supported by Elite Researcher
Grant Committee under award number (965372) from the National Institutes
for Medical Research Development (NIMAD), Tehran, Iran.
Ethics approval and consent to participate
This study was considered exempt by the NIMAD Institutional Review Board.
Consent for publication
Not applicable.
Competing interests
The authors declare no conflict of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Research Center for Biochemistry and Nutrition in Metabolic Diseases,
Kashan University of Medical Sciences, Kashan, Iran. 2Endocrinology and
Metabolism Research Center, Department of Gynecology and Obstetrics,
School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Received: 13 November 2018 Accepted: 4 January 2019
References
1. Huang CC, Tien YJ, Chen MJ, Chen CH, Ho HN, Yang YS. Symptom patterns
and phenotypic subgrouping of women with polycystic ovary syndrome:
association between endocrine characteristics and metabolic aberrations.
Hum Reprod. 2015;30:937–46.
2. Artimani T, Karimi J, Mehdizadeh M, Yavangi M, Khanlarzadeh E, Ghorbani
M, et al. Evaluation of pro-oxidant-antioxidant balance (PAB) and its
association with inflammatory cytokines in polycystic ovary syndrome
(PCOS). Gynecol Endocrinol. 2018;34:148–52.
3. Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE.
New perspectives on the pathogenesis of PCOS: neuroendocrine origins.
Trends Endocrinol Metab. 2018;29:841–52.
4. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced
oxidative stress in the development of insulin resistance and
hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab.
2006;91:336–40.
5. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade
chronic inflammation in women with polycystic ovarian syndrome. J Clin
Endocrinol Metab. 2001;86:2453–5.
6. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and
severe depressive and anxiety symptoms in polycystic ovary syndrome: a
systematic review and meta-analysis. Hum Reprod. 2017;32:1075–91.
7. van Zuuren EJ, Fedorowicz Z. Interventions for hirsutism excluding laser and
photoepilation therapy alone: abridged Cochrane systematic review
including GRADE assessments. Br J Dermatol. 2016;175:45–61.
8. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L.
reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a
post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metab.
2013;98:2944–51.
9. Shang M, Sun J. Vitamin D/VDR, probiotics, and gastrointestinal diseases.
Curr Med Chem. 2017;24:876–87.
10. Thomson RL, Spedding S, Brinkworth GD, Noakes M, Buckley JD. Seasonal
effects on vitamin D status influence outcomes of lifestyle intervention in
overweight and obese women with polycystic ovary syndrome. Fertil Steril.
2013;99:1779–85.
11. He C, Lin Z, Robb SW, Ezeamama AE. Serum vitamin D levels and polycystic ovary
syndrome: a systematic review and meta-analysis. Nutrients. 2015;7:4555–77.
12. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low
serum 25-hydroxyvitamin D concentrations are associated with insulin
resistance and obesity in women with polycystic ovary syndrome. Exp Clin
Endocrinol Diabetes. 2006;114:577–83.
13. Lagana AS, Vitale SG, Ban Frangez H, Vrtacnik-Bokal E, D'Anna R. Vitamin D
in human reproduction: the more, the better? An evidence-based critical
appraisal. Eur Rev Med Pharmacol Sci. 2017;21:4243–51.
14. Monastra G, De Grazia S, De Luca L, Vittorio S, Unfer V, Vitamin D. A steroid
hormone with progesterone-like activity. Eur Rev Med Pharmacol Sci. 2018;
22:2502–12.
15. Akbari M, Ostadmohammadi V, Lankarani KB, Tabrizi R, Kolahdooz F, Heydari
ST, et al. The effects of vitamin D supplementation on biomarkers of
inflammation and oxidative stress among women with polycystic ovary
syndrome: a systematic review and meta-analysis of randomized controlled
trials. Horm Metab Res. 2018;50:271–9.
16. Xue Y, Xu P, Xue K, Duan X, Cao J, Luan T, et al. Effect of vitamin D on
biochemical parameters in polycystic ovary syndrome women: a meta-
analysis. Arch Gynecol Obstet. 2017;295:487–96.
17. Maktabi M, Chamani M, Asemi Z. The effects of vitamin D supplementation on
metabolic status of patients with polycystic ovary syndrome: a randomized,
double-blind, placebo-controlled trial. Horm Metab Res. 2017;49:493–8.
18. Lindheim L, Bashir M, Munzker J, Trummer C, Zachhuber V, Leber B, et al.
Alterations in gut microbiome composition and barrier function are
associated with reproductive and metabolic defects in women with
polycystic ovary syndrome (PCOS): a pilot study. PLoS One. 2017;12:
e0168390. https://doi.org/10.1371/journal.pone.0168390.
19. Raygan F, Ostadmohammadi V, Asemi Z. The effects of probiotic and
selenium co-supplementation on mental health parameters and metabolic
profiles in type 2 diabetic patients with coronary heart disease: a
randomized, double-blind, placebo-controlled trial. Clin Nutr. 2018. https://
doi.org/10.1016/j.clnu.2018.07.017.
20. Karamali M, Eghbalpour S, Rajabi S, Jamilian M, Bahmani F, Tajabadi-
Ebrahimi M, et al. Effects of probiotic supplementation on hormonal
profiles, biomarkers of inflammation and oxidative stress in women with
polycystic ovary syndrome: a randomized, double-blind, placebo-controlled
trial. Arch Iran Med. 2018;21:1–7.
21. Rotterdam ESHRE. ASRM-sponsored PCOS consensus workshop group.
Revised 2003 consensus on diagnostic criteria and long-term health risks
related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
22. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications,
etiology, and management. Am J Obstet Gynecol. 1981;140:815–30.
23. Ramezani Tehrani F, Minooee S, Azizi F. Validation of a simplified method to
assess hirsutism in the Iranian population. Eur J Obstet Gynecol Reprod Biol.
2014;174:91–5.
24. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for
measuring depression. Arch Gen Psychiatry. 1961;4:561–71.
25. Goldberg DP, Hillier VF. A scaled version of the general health
questionnaire. Psychol Med. 1979;9:139–45.
26. Crawford JR, Henry JD. The positive and negative affect schedule (PANAS):
construct validity, measurement properties and normative data in a large
non-clinical sample. Br J Clin Psychol. 2004;43:245–65.
27. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh
sleep quality index: a new instrument for psychiatric practice and research.
Psychiatry Res. 1989;28:193–213.
28. Tatsch E, Bochi GV, Pereira Rda S, Kober H, Agertt VA, de Campos MM, et al.
A simple and inexpensive automated technique for measurement of serum
nitrite/nitrate. Clin Biochem. 2011;44:348–50.
29. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure
of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239:70–6.
Ostadmohammadi et al. Journal of Ovarian Research            (2019) 12:5 Page 7 of 8
30. Beutler E, Gelbart T. Plasma glutathione in health and in patients with
malignant disease. J Lab Clin Med. 1985;105:581–4.
31. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic
indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol
Med. 1990;9:515–40.
32. Jamilian M, Foroozanfard F, Rahmani E, Talebi M, Bahmani F, Asemi Z. Effect
of two different doses of vitamin D supplementation on metabolic profiles
of insulin-resistant patients with polycystic ovary syndrome. Nutrients. 2017;
9. https://doi.org/10.3390/nu9121280.
33. Mansournia MA, Altman DG. Invited commentary: methodological issues in
the design and analysis of randomised trials. Br J Sports Med. 2018;52:553–5.
34. Schmidt C. Mental health: thinking from the gut. Nature. 2015;518:S12–5.
35. Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. Gamma-
aminobutyric acid production by culturable bacteria from the human
intestine. J Appl Microbiol. 2012;113:411–7.
36. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous
bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell.
2015;161:264–76.
37. Ng QX, Peters C, Ho CYX, Lim DY, Yeo WS. A meta-analysis of the use of
probiotics to alleviate depressive symptoms. J Affect Disord. 2018;228:13–9.
38. Ju SY, Lee YJ, Jeong SN. Serum 25-hydroxyvitamin D levels and the risk of
depression: a systematic review and meta-analysis. J Nutr Health Aging.
2013;17:447–55.
39. Fernandes de Abreu DA, Eyles D, Feron F, Vitamin D. A neuro-
immunomodulator: implications for neurodegenerative and autoimmune
diseases. Psychoneuroendocrinology. 2009;34(Suppl 1):S265–77.
40. Bertone-Johnson ER. Vitamin D and the occurrence of depression: causal
association or circumstantial evidence? Nutr Rev. 2009;67:481–92.
41. Humble MB. Vitamin D, light and mental health. J Photochem Photobiol B.
2010;101:142–9.
42. Gowda U, Mutowo MP, Smith BJ, Wluka AE, Renzaho AM. Vitamin D
supplementation to reduce depression in adults: meta-analysis of
randomized controlled trials. Nutrition. 2015;31:421–9.
43. Vitale SG, Caruso S, Rapisarda AMC, Cianci S, Cianci A. Isoflavones, calcium,
vitamin D and inulin improve quality of life, sexual function, body
composition and metabolic parameters in menopausal women: result from
a prospective, randomized, placebo-controlled, parallel-group study. Prz
Menopauzalny. 2018;17:32–8.
44. Raygan F, Ostadmohammadi V, Bahmani F, Asemi Z. The effects of vitamin
D and probiotic co-supplementation on mental health parameters and
metabolic status in type 2 diabetic patients with coronary heart disease: a
randomized, double-blind, placebo-controlled trial. Prog Neuro-
Psychopharmacol Biol Psychiatry. 2018;84:50–5.
45. Reyes-Munoz E, Sathyapalan T, Rossetti P, Shah M, Long M, Buscema M, et al.
Polycystic ovary syndrome: implication for drug metabolism on assisted
reproductive techniques-a literature review. Adv Ther. 2018;35:1805–15.
46. Muscogiuri G, Altieri B, de Angelis C, Palomba S, Pivonello R, Colao A, et al.
Shedding new light on female fertility: the role of vitamin D. Rev Endocr
Metab Disord. 2017;18:273–83.
47. Vitale SG, Rossetti P, Corrado F, Rapisarda AM, La Vignera S, Condorelli RA,
et al. How to achieve high-quality oocytes? The key role of myo-inositol
and melatonin. Int J Endocrinol. 2016;2016:4987436.
48. Raja-Khan N, Shah J, Stetter CM, Lott ME, Kunselman AR, Dodson WC, et al.
High-dose vitamin D supplementation and measures of insulin sensitivity in
polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil Steril.
2014;101:1740–6.
49. Liao D, Zhong C, Li C, Mo L, Liu Y. Meta-analysis of the effects of probiotic
supplementation on glycaemia, lipidic profiles, weight loss and C-reactive
protein in women with polycystic ovarian syndrome. Minerva Med. 2018.
50. Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. The polycystic
ovary syndrome: an update on metabolic and hormonal mechanisms. J
Med Life. 2015;8:142–5.
51. Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, et al.
Weight loss and lowering androgens predict improvements in health-related
quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101:2966–74.
52. Boztosun A, Acmaz G, Ozturk A, Muderris II. Clinical efficacy of low dose
flutamide plus Diane-35 in the treatment of idiopathic hirsutism and
polycystic ovary syndrome. Ginekol Pol. 2013;84:258–62.
53. Crommen S, Simon MC. Microbial regulation of glucose metabolism and
insulin resistance. Genes. 2017;9.
54. Saydam BO, Yildiz BO. Gut-brain axis and metabolism in polycystic ovary
syndrome. Curr Pharm Des. 2016;22:5572–87.
55. Pal L, Berry A, Coraluzzi L, Kustan E, Danton C, Shaw J, et al. Therapeutic
implications of vitamin D and calcium in overweight women with
polycystic ovary syndrome. Gynecol Endocrinol. 2012;28:965–8.
56. Jamilian M, Amirani E, Asemi Z. The effects of vitamin D and probiotic co-
supplementation on glucose homeostasis, inflammation, oxidative stress
and pregnancy outcomes in gestational diabetes: a randomized, double-
blind, placebo-controlled trial. Clin Nutr. 2018. https://doi.org/10.1016/j.clnu.
2018.10.028.
57. Razzaghi R, Pourbagheri H, Momen-Heravi M, Bahmani F, Shadi J, Soleimani
Z, et al. The effects of vitamin D supplementation on wound healing and
metabolic status in patients with diabetic foot ulcer: a randomized, double-
blind, placebo-controlled trial. J Diabetes Complicat. 2017;31:766–72.
58. Mansournia MA, Ostadmohammadi V, Doosti-Irani A, Ghayour-Mobarhan M,
Ferns G, Akbari H, et al. The effects of vitamin D supplementation on
biomarkers of inflammation and oxidative stress in diabetic patients: a
systematic review and meta-analysis of randomized controlled trials. Horm
Metab Res. 2018;50:429–40.
59. Chen N, Wan Z, Han SF, Li BY, Zhang ZL, Qin LQ. Effect of vitamin D
supplementation on the level of circulating high-sensitivity C-reactive protein:
a meta-analysis of randomized controlled trials. Nutrients. 2014;6:2206–16.
60. Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E,
et al. Clinical and metabolic response to probiotic supplementation in
patients with multiple sclerosis: a randomized, double-blind, placebo-
controlled trial. Clin Nutr. 2017;36:1245–9.
61. Kasinska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a
meta-analysis. Pol Arch Med Wewn. 2015;125:803–13.
62. Jamka M, Wozniewicz M, Walkowiak J, Bogdanski P, Jeszka J, Stelmach-
Mardas M. The effect of vitamin D supplementation on selected
inflammatory biomarkers in obese and overweight subjects: a systematic
review with meta-analysis. Eur J Nutr. 2016;55:2163–76.
63. Pawelczak M, Rosenthal J, Milla S, Liu YH, Shah B. Evaluation of the pro-
inflammatory cytokine tumor necrosis factor-alpha in adolescents with
polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2014;27:356–9.
64. Boots CE, Jungheim ES. Inflammation and human ovarian follicular
dynamics. Semin Reprod Med. 2015;33:270–5.
65. Sadrzadeh-Yeganeh H, Elmadfa I, Djazayery A, Jalali M, Heshmat R, Chamary
M. The effects of probiotic and conventional yoghurt on lipid profile in
women. Br J Nutr. 2010;103:1778–83.
66. Al-Rasheed NM, Al-Rasheed NM, Bassiouni YA, Hasan IH, Al-Amin MA, Al-
Ajmi HN, et al. Vitamin D attenuates pro-inflammatory TNF-alpha cytokine
expression by inhibiting NF-small ka, CyrillicB/p65 signaling in
hypertrophied rat hearts. J Physiol Biochem. 2015;71:289–99.
Ostadmohammadi et al. Journal of Ovarian Research            (2019) 12:5 Page 8 of 8
